Cormorant Asset Management’s X4 Pharmaceuticals XFOR Stock Holding History

Cormorant Asset Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-54,299	Closed	-$1.42M	–	78
2023 Q1	$1.42M	Hold	54,299	–	–	0.09%	62
2022 Q4	$1.62M	Buy	54,299 +26,611	+96%	+$1.26M	0.11%	62
2022 Q3	$1.42M	Buy	27,688 +24,222	+699%	+$837K	0.1%	63
2022 Q2	$100K	Hold	3,466	–	–	0.01%	80
2022 Q1	$182K	Hold	3,466	–	–	0.01%	77
2021 Q4	$238K	Hold	3,466	–	–	0.01%	77
2021 Q3	$550K	Hold	3,466	–	–	0.02%	85
2021 Q2	$676K	Hold	3,466	–	–	0.02%	98
2021 Q1	$895K	Hold	3,466	–	–	0.02%	113
2020 Q4	$669K	Buy	+3,466	New	+$681K	0.02%	104
2020 Q3	–	Sell	-10,966	Closed	-$1.76M	–	96
2020 Q2	$1.76M	Sell	10,966 -421	-4%	-$115K	0.07%	78
2020 Q1	$3.42M	Buy	11,387 +2,962	+35%	+$840K	0.16%	64
2019 Q4	$2.7M	Sell	8,425 -20,964	-71%	-$7.52M	0.11%	65
2019 Q3	$11.2M	Sell	29,389 -291	-1%	-$115K	0.68%	42
2019 Q2	$13.4M	Buy	29,680 +21,255	+252%	+$10.8M	0.77%	40
2019 Q1	$4.4M	Sell	8,425 -1,918	-19%	-$1.06M	0.3%	52
2018 Q4	$4.32M	Buy	+10,343	New	+$3.95M	0.35%	51

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Cormorant Asset Management's XFOR Position: Q2 2023 in Review

Cormorant Asset Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2023, closing a stake of 54,299 shares — an estimated $1.42M sold.

Cormorant Asset Management first reported a position in XFOR in Q4 2018 and held it in 17 quarters. The position peaked at $13.4M in Q2 2019. 95 funds tracked by Wall St. Rank hold XFOR as of Q2 2023.

Cormorant Asset Management reported no remaining X4 Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Cormorant Asset Management sold 54,299 X4 Pharmaceuticals shares in Q2 2023, an estimated $1.42M.
Cormorant Asset Management first reported a position in X4 Pharmaceuticals in Q4 2018 and held it in 17 quarters.
Cormorant Asset Management's X4 Pharmaceuticals position peaked at $13.4M in Q2 2019.
95 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.